# EDGAR Filing Document

**Accession Number:** 0001858685
**File Stem:** 0001641172-25-023006
**Filing Date:** 2025-8
**Character Count:** 46891
**Document Hash:** bd5017f6cd561f66c6875375653db3c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-023006.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001641172-25-023006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20250811

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biofrontera Inc.
- **CENTRAL INDEX KEY:** 0001858685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473765675
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40943
- **FILM NUMBER:** 251202954

**BUSINESS ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 781-245-1325

**MAIL ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): August 11, 2025** 

**Biofrontera Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40943** | **47-3765675** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **120 Presidential Way, Suite 330**<br> **Woburn, Massachusetts** | **01801** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (781) 245-1325**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common stock, par value $0.001 per share** | **BFRI** | **The Nasdaq Stock Market LLC** |
| **Preferred Stock Purchase Rights** |  | **The Nasdaq Stock Market LLC** |
| **Warrants** | **BFRIW** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item** **5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

*Appointment of George Jones as Chief Commercial Officer*

On August 11, 2025, Biofrontera Inc. (the "Company") announced that, starting on August 25, 2025, George Jones will serve as the Chief Commercial Officer of the Company. Mr. Jones is an experienced commercial executive with more than 25 years of commercial leadership experience in the pharmaceutical and biotech sectors. Prior to joining the Company, Mr. Jones (age 52) recently served as Chief Operating Officer at UpScriptHealth since 2021. Prior to UpScriptHealth, Mr. Jones held senior commercial roles at Currax Pharmaceuticals since 2015.

The Company has entered into an Employment Agreement with Mr. Jones. The following description of the Employment Agreement is not complete and is qualified in its entirety by reference to the Employment Agreement filed as Exhibit 10.1 hereto and incorporated herein by reference.

The Employment Agreement entitles Mr. Jones to, among other benefits, the following compensation:

● An annual base salary of $315,000.00

● A bonus of up to 50% of his base salary, upon attainment of performance goals set in advance by the Company's board of directors

● Receipt of no less than 100,000 stock options, one-third of which shall be awarded following completion of each of the first three full years of service and which shall be subject to a one-year vesting schedule and other terms, conditions, and restrictions imposed upon all awards under the Company's employee stock option program

● Participation in the Company's employee benefit programs and arrangements that the Company makes available to its employees

In the event that Mr. Jones experiences a termination of his employment without "cause" or he resigns for "good reason" outside of period during which provisions related to a "change in control" (as such terms are defined in the employment agreement) are in effect, provided that he executes and makes effective a release of claims against the Company and its affiliates, Mr. Jones will become entitled to a lump sum payment in an amount equal to one-twelfth of his annual base salary for each full year of employment; further provided that such payment will not be less than six months of, nor than two full years of, his then-current base salary. If Mr. Jones experiences a termination of his employment without "cause" or he resigns for "good reason" within a certain period of a "change in control," he will be entitled to certain benefits and an enhanced severance payment. The Employment Agreement contains customary expense reimbursement, indemnification, non-disclosure, non-competition, and non-solicitation provisions.

Other than his Employment Agreement, there are no arrangements or understandings between Mr. Jones and any other person with respect to his appointment, and Mr. Jones has no family relationship with any director or executive officer of the Company. Mr. Jones is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On August 11, 2025 the Company issued a press release announcing the appointment described in Item 5.02 of this Current Report on Form 8-K (the "Form 8-K"). The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

10.1 [Employment Agreement dated July 18, 2025](ex10-1.htm) <br> 99.1 [Press release dated August 11, 2025](ex99-1.htm) <br> 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **August 11, 2025** | **Biofrontera Inc.** |
| (Date) | (Registrant) |
|  | */s/ E. Fred Leffler, III* |
|  | E. Fred Leffler, III |
|  | *Chief Financial Officer* |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

**<u>EMPLOYMENT AGREEMENT</u>**

This Employment Agreement (the "Agreement") is made as of July 18, 2025 (the "Effective Date"), by and between Biofrontera, Inc, a Delaware corporation (the "Company") having its principal office at 120 Presidential Way, Suite 330, Woburn, MA 01801 and George P. Jones, an individual residing in Green Brook, New Jersey (the "Executive").

**<u>BACKGROUND INFORMATION</u>**

The Company wishes to secure the employment services of the Executive for an indefinite period of time and upon the particular terms and conditions hereinafter set forth. The Executive is willing to be so employed. Accordingly, the parties agree as follows:

**<u>AGREEMENT</u>**

**1.** **EMPLOYMENT AND TERM** 

Starting on August 25, 2025 (the "Start Date"), the Company hereby agrees to employ Executive, and Executive hereby accepts employment by the Company, on the terms and conditions hereinafter set forth. Executive term of employment by the Company under this Agreement (the "**Term**") shall commence on the Start Date and end on the date on which the term of employment is terminated in accordance with Section 5. Executive's employment with the Company shall be on an "at-will" basis.

**2.** **POSITION; DUTIES AND RESPONSIBILITIES; LOCATION** 

During the Term, the Company shall employ Executive as its Chief Commercial Officer. Executive shall report directly to the Chief Executive Officer, subject to the specific direction of the Company's Board of Directors (the "Board"). Executive shall have general overall authority and responsibility for all Company commercial functions and shall have other duties, powers, and authority as are commensurate with their position as Chief Commercial Officer and such other duties and responsibilities that are commensurate with their positions as specifically delegated to him or her from time to time by the Chief Executive Officer and/or the Board.

Executive agrees to devote their efforts, energies, and skill to the discharge of the duties and responsibilities attributable to their position and, except as set forth herein, agrees to devote all of their professional time and attention to the business and affairs of the Company. Executive may only pursue non-competitive activities that do not interfere with the complete performance of their obligations hereunder, as determined by the Board in its sole reasonable discretion.

Executive shall be subject to the Bylaws, policies, practices, procedures and rules of the Company, including those policies and procedures set forth in the Company's Code of Conduct. Executive's violation of the terms of such documents shall be considered a breach of the terms of this Agreement.

![](ex10-1_001.jpg)

Executive's principal place of employment shall be Executive's primary residence, which is currently located in Green Brook, New Jersey. Executive will be required to routinely travel (including but not limited to regular travel to the Company's headquarters, which is currently located in Woburn, MA) as directed by the Chief Executive Officer.

**3.** **COMPENSATION** 

During the Term, the Company shall pay to Executive an annual salary of $315,000 (the "Base Salary"), subject to agreed upon and/or legally required deductions, including but not limited to Federal and State income tax withholdings. The Base Salary shall be paid in accordance with the Company's customary payroll procedure. The Executive is eligible to participate in the Company's annual merit review process, by which the Board may, in its sole discretion, increase Executive's Base Salary without the need to formally amend this Agreement.

Executive shall be eligible to receive a cash bonus of up to 50% of their Base Salary upon the attainment of individual and company performance goals set in advance by the Board. All such bonuses shall be paid after the completion of the Company's financial statements for the applicable fiscal year as and when bonuses are paid to members of senior management generally. The actual amount of Executive's bonus shall depend upon the level of achievement of set targets, however no bonus shall be paid if the level of target achievement is below 70%.

Executive shall also be eligible to participate in Company's stock option plan. The number of options awarded and timing of any such awards shall be subject to the terms of the Company's Omnibus Incentive Plan and at the sole discretion of the Board. Notwithstanding the above, the parties agree that Executive shall be awarded no less than, in aggregate, 100,000 stock options, one-third of which shall be awarded following completion of each of the first three full years of service.

**4.** **VACATION; BENEFITS; REIMBURSEMENT OF EXPENSES** 

During the Term, Executive shall be entitled to participate in such health, group insurance, welfare, pension, and other employee benefit plans, programs, and arrangements as are made generally available from time to time to other employees of the Company, subject to Executive's satisfaction of all applicable eligibility conditions of such plans, programs, and arrangements. Nothing herein shall be construed to limit the Company's ability to amend or terminate any employee benefit plan or program in its sole discretion.

Executive shall further be entitled to paid time off in accordance with the Company's standard policies applicable to all employees. Timing of vacations shall be reasonably exercised by the Executive. Additionally, Executive shall be entitled to (a) such leave by reason of physical or mental disability or incapacity and to such participation in medical and life insurance, pension benefits, disability and other fringe benefit plans as the Company may make generally available to all of its executives and other employees from time to time, and (b) reimbursement for all normal and reasonable expenses necessarily incurred in the performance of their obligations hereunder, subject to such reasonable substantiation requirements as may be imposed by the Company to all employees of the Company.

![](ex10-1_001.jpg)

**5.** **MODIFICATION AND TERMINATION** 

---

| | |
|:---|:---|
| a. | **<u>Modification.</u>** Except as described in Section 3 regarding Executive's eligibility to participate in the Company's annual merit review process, the Agreement may only be amended or modified with the mutual written consent of the parties, and in its present form consists of the entire Agreement between and amongst the parties. |
| b. | **<u>Termination; General.</u>** The Agreement may be terminated by either party by giving thirty (30) days' notice to the other party, or by the Company immediately upon the occurrence of any one of the following events: (a) the death of the Executive, (b) the occurrence to Executive of a physical or mental disability which, in the judgment (reasonably exercised) of the Board, renders Executive unable to perform their normal duties on behalf of the Company for a continuous period of three (3) months (measured from the first day of the month immediately following the occurrence of such disability) (a "Disability"); or (c) a determination by the Board that there is Cause (as defined in Section 5(d) below) to terminate Executive's employment. |
|  | In the event that this Agreement is terminated for any reason, Executive will be entitled to receive (a) accrued but unpaid Base Salary through the termination date; (b) reimbursement for any unreimbursed pre-approved reasonable business expenses incurred through the termination date; (c) accrued but unused PTO days; and (d) all other payments, benefits, or fringe benefits to which Executive shall be entitled as of the termination date under the terms of any applicable compensation arrangement or benefit, equity, or fringe benefit plan or program or grant (the "Accrued Benefits") and shall have no further rights to any compensation or benefits from the Company unless as stated in this Section 5. |
|  | Upon termination of Executive's employment for any reason or under any circumstances, Executive shall promptly return any and all of the property of the Company and any affiliates (including, without limitation, all computers, keys, credit cards, identification tags, documents, data, confidential information, work product, and other proprietary materials), and other materials. In its sole discretion, the Company may direct Executive, and Executive agrees to comply with any such direction, to delete or destroy any and all copies of such documents and materials that are not or cannot be returned to the Company that remain in Executive's possession or control. At the Company's request, Executive shall confirm in writing that all of the above have been returned or destroyed. |

---

![](ex10-1_001.jpg)

c.  **<u>Termination for Cause or By Executive Without Good Reason.</u>** In the event that Executive's employment hereunder is terminated by
 the Company for Cause or by Executive without Good Reason, Executive shall be entitled to receive the Accrued Benefits.

---

| | |
|:---|:---|
|  | For purposes of the Agreement, the term "Cause" shall include, (i) Executive's breach of this Agreement, which, if curable, remains uncured or continues after fifteen (15) days' notice by the Company thereof; (ii) Executive's material negligence or dereliction in the performance of, or failure to perform Executive's duties of employment with the Company, which remains uncured or continues after fifteen (15) days' notice by the Company thereof; (iii) Executive's repeated or willful violation of any provision of the state or federal laws or regulations, the Company's By-Laws, or the Company's other stated policies, standards, practices, or procedures, which remain uncured or continue after fifteen (15) days' notice by the Company thereof; (iv) Executive's commission of any crime constituting a felony in the jurisdiction in which committed, any act involving moral turpitude (whether or not a felony), or any other criminal act involving embezzlement, misappropriation of money, fraud, theft, or bribery (whether or not a felony); (v) a determination that Executive has demonstrated a dependence upon any addictive substance, including but not limited to alcohol, controlled substances, narcotics or barbiturates, and that said dependency has or may negatively impact Executive's ability to perform their duties as described herein; or (vi) Executive's refusal to carry out a lawful directive of the Company, which directive is consistent with the scope and nature of Executive's responsibilities, which remain uncured or continue after fifteen (15) days' notice by the Company thereof. In addition, Executive's employment shall be deemed to have terminated for Cause if, on the date Executive's employment terminates, facts and circumstances exist that would have justified a termination for Cause, even if such facts and circumstances are discovered after such termination. |
| d. | **<u>Termination Without Cause, By Executive for Good Reason, or Due to Disability.</u>** In the event that Executive's employment hereunder is terminated by the Company without Cause, by Executive for Good Reason, or due to Executive's Disability, Executive shall be entitled to receive 1) the Accrued Benefits, and 2) a lump sum payment of an amount equal to one-twelfth of his annual base salary for each full year of employment; further provided that such payment will not be less than six months of, nor more than two full years of, his then-current base salary (the "Severance Payment"); provided, however, that the Severance Payment shall be conditioned upon the execution, non-revocation, and delivery of a general release of claims by Executive, in a form reasonably satisfactory to the Company (the "Release"), within thirty (30) days following the termination date (or within the timeframe stated in the Release, if longer than thirty (30) days). Payment of the Severance Payment shall be made on the first payroll date following Executive's execution of the Release. In the event that Executive fails to timely execute and deliver the Release, the Company shall have no obligation to pay Severance Payment under this Agreement. |
|  | If Executive is terminated by the Company without Cause, or by Executive for Good Reason, within three months prior to or 12 months after a Change In Control, he will be entitled to certain benefits pertaining to continuing health insurance coverage and an enhanced severance payment, both as defined by Section 9 of this Agreement. |

---

For the purposes of this Agreement, "Good Reason" shall mean a material breach by the Company of its obligations under this Agreement, upon which Executive notifies the Board in writing of such material breach within thirty (30) days of such occurrence and such material breach shall have not been cured within thirty (30) days after the Company's receipt of written notice thereof from Executive. Executive's resignation will not be treated as being for Good Reason unless Executive's resignation occurs during the two (2) month period following the end of the cure period. For the avoidance of doubt, a change in Executive's title or modification to Executive's duties and responsibilities attributable to their position shall not constitute a material breach of this Agreement.

![](ex10-1_001.jpg)

---

| | |
|:---|:---|
| e. | **<u>Termination Due to Death.</u>** In the event of the Executive's death, Executive's estate (or, at Executive's option, a designated beneficiary) shall receive all Accrued Benefits and Executive's base compensation otherwise due for the succeeding three (3) full calendar months following their death (calculated starting on the first calendar day following Executive's death), paid on a monthly basis. |
| f. | **<u>Resignation as an Officer or Director.</u>** Immediately upon any termination of Executive's employment for any reason, Executive shall be deemed to have resigned any position he may then hold as an officer of the Company or a member of the Board of Directors or similar body of any of Company's affiliates, and as a fiduciary of any Company benefit plan. |
| g. | **<u>Post-Termination Cooperation; Non-Assistance.</u>** Executive agrees and covenants that, following the Term, he or she shall, to the extent requested by the Company, cooperate in good faith with the Company to assist the Company in the pursuit or defense of (except if Executive is adverse with respect to) any claim, administrative charge, or cause of action by or against the Company as to which Executive, by virtue of his or her employment with the Company or any other position that Executive holds that is affiliated with or was held at the request of the Company, has relevant knowledge or information, including by acting as the Company's representative in any such proceeding and, without the necessity of a subpoena, providing truthful testimony in any jurisdiction or forum. The Company shall reimburse Executive for his or her reasonable out-of-pocket expenses incurred in compliance with this Section. |
|  | Executive further agrees and covenants that, following the Term, they shall not voluntarily assist, support, or cooperate with, directly or indirectly, any person or entity alleging or pursuing or defending against any claim, administrative charge, or cause or action against or by the Company, including by providing testimony or other information or documents, except under compulsion of law. Should Executive be compelled to testify, nothing in this Agreement is intended or shall prohibit Executive from providing complete and truthful testimony. Nothing in this Agreement shall in any way prevent Executive from cooperating with any investigation by any federal, state, or local governmental agency. |

---

![](ex10-1_001.jpg)

**6.**  **<u>CONFIDENTIAL INFORMATION AND PROPRIETARY INTERESTS</u>** 

Executive acknowledges that as the Chief Commercial Officer, they will receive Company's Confidential Information. Executive recognizes that all such Confidential Information is and shall remain the sole property of the Company, free of any rights of Executive, and acknowledges that the Company has a vested interest in assuring that all such Confidential Information remains secret and confidential. Therefore, Executive agrees that during or after the expiration of their term of employment with the Company, the Executive shall not communicate or divulge to, or use for the benefit of, any individual, association, partnership, trust, corporation or other entity except the Company, any Confidential Information received by the Executive by virtue of their employment, without first being in receipt of the Company's written consent to do so.

For the purposes of this Agreement, the term "Confidential Information" means:

a. All
 information developed or used by the Company or its associates relating to business operations, including but not limited to customer
 lists, purchase orders, supplier or distributor information, financial data, pricing information and price lists, business plans,
 marketing strategies, personnel records, and all books, records, manuals, advertising materials, catalogues, correspondences, mailing
 lists, production data, and purchasing materials; and

b. All
 proprietary information of the company (or any records related to the same), including but not limited to all trade secrets, inventions,
 processes, procedures, research records, market surveys or marketing know-how, trademarks, copyrights, patents, and patent applications.

The term "Confidential Information" shall not include information that is or becomes generally known to the public other than as a result of a disclosure by Executive in violation of this Agreement, or by any other employee of the Company subject to confidentiality obligations.

**7.**  **<u>NON-COMPETITION/NON-SOLICITATION</u>** 

During the term of their employment hereunder and for the one (1) year period following the termination hereof for any reason other than the Company's dissolution or discontinuance of business activities (the "Restricted Period") the Executive shall not, and will cause his or her affiliates not to, directly or indirectly, through or in association with any third party, in any territory which the Company operates as of the time Executive is no longer employed by, consulting for, serving as a board member of, or no longer otherwise works for, the Company, (i) engage in, market, sell, or provide any products or services which are the same or similar to or otherwise competitive with the products and services sold or provided by the Company or (ii) own, acquire, or control any interest, financial or otherwise, in a third party or business or manage, participate in, consult with, render services for or otherwise, any business, that in each case is engaged in selling or providing the same, similar or otherwise competitive services or products which the Company is selling or providing, other than ownership of five percent (5%) or less of the equity of a publicly traded company. The parties expressly agree that the duration and geographical area of the restrictive covenant are reasonable.

The covenant shall be construed as an agreement independent of any other provision herein; and the existence of any claim or cause of action of the Executive against the Company regardless of how arising, shall not constitute a defense to the enforcement by the Company or its terms. If any portion of the covenant is held by a court to be unenforceable with respect either to its duration or geographical area, for whatever reason, it shall be considered divisible both as to time and geographical area, resulting in an intended requirement that the longest lesser period of time or largest lesser geographical area found by such court to be a reasonable restriction shall remain an effective restrictive covenant, specifically enforceable against the Executive.

![](ex10-1_001.jpg)

Additionally, during the Executive's employment with the Company and thereafter during the Restricted Period, the Executive shall not, and shall not permit any third party subject to Executive's direction or control to, directly or indirectly, (i) call upon, accept business from, or solicit the business of any Person who is, or who had been at any time during the preceding twelve months, a customer or supplier of the Company, (ii) otherwise divert or attempt to divert any business from the Company, (iii) interfere with the business relationships between the Company and any of its customers, suppliers or others with whom they have business relationships or (iv) recruit or otherwise solicit or induce, or enter into or participate in any plan or arrangement to cause, any Person who is an employee of, or otherwise performing services for, the Company to terminate their or her employment or other relationship with the Company, or hire any Person who has left the employ of or ceased providing services to the Company during the Restricted Period.

**8.**  **<u>REMEDIES FOR BREACH OF EXECUTIVE OBLIGATIONS</u>** 

The parties to the agreement agree that the services of the Executive are of a personal, specific, unique and extraordinary character and cannot be readily replaced by the Company. They further agree that in the course of performing their services, the Executive will have access to various types of proprietary information of the Company, which, if released to others or used by the Executive other than for the benefit of the Company, in either case without the Company's written consent, could cause the Company to suffer irreparable injury. Therefore, the obligation of the Executive established under Section 6 and Section 7 hereof shall be enforceable both at law and in equity, by injunction, specific performance, damages or other remedy; and the right of the Company to obtain any such remedy shall be cumulative and not alternative and shall not be exhausted by any one or more uses thereof. Any adjudication against Executive by the Company shall be in accordance with the laws of Massachusetts and Massachusetts Executive rights.

**9.**  **<u>Change IN Control</u>** 

If Executive's termination of employment occurs within 3 months prior to or 12 months after a Change In Control (as defined in this Section 9) and such termination is either (i) without Cause or, (ii) by Executive for Good Reason (as defined by Section 5(d) above), then Executive shall be entitled to receive, in lieu of the severance amount described in Section 5, a severance amount equal to each of (a) their current base salary, and (b) their target annual bonus for the then current fiscal year. Additionally, subject to the Executive's copayment of premium amounts at the current rate at the time of termination, the Executive may continue to participate in the Company's group health, dental and vision program for 3 months; provided, however, that the continuation of health benefits under this Section shall reduce and count against the Executive's rights under COBRA.

![](ex10-1_001.jpg)

For the purposes of this Agreement, and subject to the exception described below, a "Change In Control" shall mean the occurrence of any of the following events after the Effective Date:

a. The approval by stockholders of the Company of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Any
 consolidation or merger of the Company in which the Company is not the continuing or surviving corporation, or

2. A
 sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all the
 assets of the Company to a party which is not controlled by the Company;

b. Either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The
 receipt by the Company of a report on schedule 13D, or an amendment to such a report, filed with the Securities and Exchange Commission
 ("SEC") pursuant to Section 13(d) of the Securities Exchange Act of 1934 (the "1934 Act") disclosing that
 any person, group, company, corporation, or other entity has become the beneficial owner, directly or indirectly, of 50% or more
 of the outstanding stock of the Company, or

2. The
 actual knowledge by the Company of facts, on the basis of which any person is required to file such a report on schedule 13D, a similar
 report, or an amendment to such a report, with the SEC (or would be required to file such a report or amendment upon the lapse of
 the applicable period of time specified in Section 13(d) of the 1934 Act) disclosing that such a person has become the beneficial
 owner, directly or indirectly, of 50% or more of the outstanding stock of the Company;

c. The
 purchase by any "person" (as defined in Section 13(d) of the 1934 Act), corporation or other entity, other than the Company
 or a wholly owned subsidiary or a parent company of the Company, of shares pursuant to a tender or exchange offer, to acquire any
 stock of the Company (or securities convertible into stock) for cash, securities or any other consideration provided that, after
 consummation of the offer, such person, group, corporation or other entity has become the beneficial owner (as defined in rule 13d-3
 under the 1934 Act), directly or indirectly, of 50% or more of the outstanding stock of the Company (calculated as provided in paragraph
 (d) of Rule 13d-3 under the 1934 act in the case of rights to acquire stock); or

d. The
 combination or merger of the Company with another company in which the Company is the surviving corporation but, immediately after
 the combination, the shareholders of the Company immediately prior to the combination do not hold, directly or indirectly, more than
 50% of the voting stock of the combined company (therefore being excluded from the number of shares held by such shareholders, but
 not from the voting stock of the combined company, any shares received by affiliates (as defined in the rules of the Securities and
 Exchange Commission) of such other company in exchange for stock of such other company).

Notwithstanding the above, any issuance(s) of stock of the Company to Biofrontera AG (or to third party investors) in relation to the asset purchase transaction occurring on or about June 30, 2025 in amount that are equal to or in excess of the amounts described in Sections 9(a-d) above shall not constitute a Change In Control.

![](ex10-1_001.jpg)

**10.**  **<u>INDEBTEDNESS OF EXECUTIVE</u>** 

If, during the course of their employment, Executive becomes indebted to the Company for any reason, the Company shall, if it so elects, have the right to set off and to collect any sums due it from the Executive out of any amounts which it may owe to the Executive for unpaid compensation. In the event that the Agreement terminates for any reason, all sums owed by the Executive to the Company shall become immediately due and payable.

**11.**  **<u>MISCELLANEOUS PROVISIONS</u>** 

a.  **<u>Non-assignment:</u>** Neither the Agreement nor any right or interest hereunder shall be assigned by the Executive or their legal representatives.

b.  **<u>Enforcement:</u>** If any term or condition or the Agreement shall be invalid or deemed unenforceable to any extent or in any application, then the
 remainder of the Agreement, and such terms or conditions except to such extent or in such application, shall not be affected thereby,
 and each and every term and condition of the Agreement shall be valid and enforced to the fullest extent and in the broadest application
 permitted by law.

c.  **<u>Notice:</u>** All notices or other communications required or permitted to be furnished pursuant to the Agreement shall be in writing and shall
 be considered as delivered when received by the recipient.

d.  **<u>Application of Massachusetts Law:</u>** The Agreement, and the application or interpretation thereof, shall be governed exclusively by its
 terms and by the laws of the State of Massachusetts. Venue shall be deemed located in Middlesex County, Massachusetts.

e.  **<u>Counterparts:</u>** The Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together
 shall constitute on and the same instrument.

f.  **<u>Binding Effect:</u>** Each of the provisions and agreements herein contained shall be binding upon and inure to the benefit of the personal
 representatives, devisees, heirs, successors, transferees and assigns of the respective parties hereto.

g.  **<u>Cooperation:</u>** During and following the active life of this Agreement, Executive shall give Executive's assistance and cooperation willingly,
 upon reasonable notice (which shall include due regard to the extent reasonably feasible for Executive's employment obligations
 and prior commitments), in any matter relating to Executive's position with the Company or Executive's knowledge as a
 result thereof as the company may reasonably request, including Executive's attendance and truthful testimony where deemed
 appropriate by the Company, with respect to any investigation or the Company's defense or prosecution of any existing or future
 claims or litigations or other proceeding relating to matters in which he was involved or had knowledge by virtue of Executive's
 employment with the Company. The Company will reimburse Executive for reasonable out-of-pocket travel costs and expenses incurred
 by Executive (in accordance with Company policy) as a result of providing such assistance.

![](ex10-1_001.jpg)

h.  **<u>Indemnification:</u>** The Company hereby agrees to indemnify Executive and hold Executive harmless to the fullest extent permitted by law and under the
 bylaws of the Company against and in respect to any and all actions, suits, proceedings, claims, demands, judgements, costs, expenses
 (including reasonable attorney's fees), losses, and damages resulting from Executive's good faith performance of their
 duties and obligations with the Company, except in the case of gross negligence or willful misconduct, whether or not such claims,
 demands, judgements, costs, expenses, losses, and damages are asserted or filed during the active life of this Agreement.

i.  **<u>Survival:</u>** The Parties' obligations under Sections 5(f), 5(g), 6, 7, 8, 10, and 11 shall survive the Termination of this agreement.

---

| |
|:---|
| **<u>IN WITNESS WHEREOF, the parties have executed the Agreement,</u>** |
| **COMPANY** |
| Hermann Luebbert; CEO and Chairman |
| Biofrontera Inc. |
| Date |
| **EXECUTIVE** |
| George P. Jones |
| Date |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Biofrontera Inc. Appoints George Jones as Chief Commercial Officer**

**Woburn, MA, August 11, 2025 – Biofrontera Inc. (Nasdaq: BFRI) (the "Company")**, a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert.

This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and all patents, from its former parent company – Biofrontera AG. As announced, the Company will now pay a monthly Ameluz<sup>®</sup> royalty between 12% and 15%, as opposed to the previously effective transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. These changes will bring Biofrontera significantly closer to cash break-even.

Hiring a CCO in this transformational situation will further strengthen the Company's unparalleled commercial and clinical efforts in the PDT field. Mr. Jones brings over 25 years of extensive commercial leadership experience within the specialty pharmaceutical and biotech sectors.

Mr. Jones' career is marked by a demonstrated ability to build and lead commercial organizations. At Currax Pharmaceuticals, as Vice President Global Marketing and Commercial Operations and one of the earliest employees following the company's restructuring, he was instrumental in the build out of the commercial organization, including supporting the establishment of the marketing department, sales force and training functions. He guided the young company through a period of rapid growth while simultaneously navigating the early stages of the global pandemic. While at Currax Mr. Jones also led the development of a first-in-market digital ecosystem, driving direct patient demand via social media linked to telemedicine.

Prior to Currax, at Pernix Therapeutics, Mr. Jones was promoted to Vice President of Sales and Marketing and implemented an efficient and focused sales strategy that supported rapid growth while lowering the cost structure. Earlier in his career, at Depomed, Inc. while a Senior Director of Marketing, his efforts supported the company's inorganic growth strategy successfully leading the marketing integration and re-launch of five product acquisitions.

Most recently, Mr. Jones served as Chief Operating Officer at UpScriptHealth. He was appointed to drive change and support the evolution of the leading telehealth technology platform. Under his guidance, UpScriptHealth achieved substantial growth, including a more than threefold increase in partnership revenues. This experience underscores his expertise in leveraging innovative channels to enhance patient access to therapies.

"George's proven track record of building high-performing teams, driving sustainable growth, and delivering patient-centric commercial solutions at mid-sized pharmaceutical companies makes him the ideal leader to accelerate Biofrontera's continued growth," said Dr. Hermann Luebbert. "His deep expertise in commercial leadership combined with modern approaches like digital marketing will be invaluable as we continue to expand Ameluz<sup>®</sup> in the PDT space, and George's extensive market access experience will be instrumental for our continued commercial success."

"I am thrilled to join Biofrontera at such an exciting time in its evolution," said Mr. Jones. "The company's commitment to breakthrough dermatology treatments and its focus on patient outcomes align closely with my passion for bringing innovative therapies to market. I look forward to working with our commercial organization and cross-functional partners to deliver value for patients, physicians, and stockholders."

**About Biofrontera Inc.**

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz<sup>®</sup> with the RhodoLED <sup>®</sup> lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit <u>www.biofrontera-us.com</u> and follow Biofrontera on <u>LinkedIn</u> and <u>X</u>.

**Forward-Looking Statements**

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; whether the market opportunity for Ameluz<sup>®</sup> in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company's expectations; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission (the "SEC"), which can be obtained on the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Contacts:

Investor Relations

Andrew Barwicki

1-516-662-9461

<u>ir@bfri.com</u>